Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 15.89M -69.0% |
| Revenue (ttm) | 1.21M -27.7% |
| Net Income | -28.46M |
| EPS | -9.70 |
| Shares Out | 6.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 999 |
| Open | 257.00 |
| Previous Close | 261.40 |
| Day's Range | 257.00 - 262.00 |
| 52-Week Range | 250.10 - 3,000.00 |
| Beta | 0.00 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat... [Read more]
Financial Performance
In 2025, Can-Fite BioPharma's revenue was $405,000, a decrease of -39.91% compared to the previous year's $674,000. Losses were -$9.83 million, 24.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Can-Fite Highlights Long-Term Outcome From Investigational Liver Cancer Treatment Study
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company developing treatments for cancer and inflammatory diseases, announced Monday that a patient with advanced liver cance...
Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
Can-Fite BioPharma Ltd. announced that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival. The patient, whos...
Can-Fite BioPharma Namodenoson patient reaches 10-year survival in liver cancer
Can-Fite BioPharma (CANF) announced that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival and remains…
Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
Patient from the Company's completed Phase II study remains cancer-free and in good health at the ten-year survival milestone Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Lt...
Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
Company to leverage positive Phase IIa pancreatic cancer results presented at ESMO 2026, two pivotal Phase III programs, and expanding patent protection to advance global partnering opportunities
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat ...
Can-Fite Presents Final Phase 2a Data For Namodenoson In Pancreatic Cancer
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company developing small molecule therapeutics, announced the final data from its Phase 2a clinical study of namodenoson in a...
Can-Fite BioPharma Ltd. Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Can-Fite BioPharma Ltd. announced the presentation of final positive data from its Phase IIa clinical study of namodenoson in advanced pancreatic ductal adenocarcinoma at the European Society for Medi...
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months...
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept...
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma Earnings release: Q2 2026
Can-Fite BioPharma released its Q2 2026 earnings on September 8, 2026, summarizing the period's financial results.
Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company, on Wednesday announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase...
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipe...
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
Can-Fite BioPharma (CANF) announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcino...
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma files $100M mixed securities shelf
16:17 EDT Can-Fite BioPharma (CANF) files $100M mixed securities shelf
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Can-Fite Releases Positive Data For Namodenoson In Treating Pancreatic Cancer
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company, on Monday announced positive preclinical findings indicating that Namodenoson enhanced the anti-cancer effect of gem...
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE ...
Can-Fite Advances Phase III Programs; Namodenoson Retains FDA Fast Track Status
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company developing small-molecule therapies for oncological and inflammatory diseases, provided an update on the regulatory s...
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- C...
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
Can-Fite BioPharma (CANF) announced the submission of a Phase 2 clinical study protocol to Bambino Gesu Children’s Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patient...